



# Johnson & Johnson's life-enhancing innovation & operational excellence are founded in:


## OUR PURPOSE

We blend , science and ingenuity to profoundly change the trajectory of health for humanity

## OUR PEOPLE


~142,000 employees serving more than 1 billion people each day

## OUR FINANCIAL STRENGTH

 Largest and most broadly based healthcare products company in the world

 Strong global positions across multiple franchises and therapeutic areas

 Robust and well diversified innovation platforms

 Consistent and solid financial returns

## OUR PATH FORWARD

 Enterprise

Focus on achieving near-term financial targets, maintaining high quality standards, and continuing to invest for long-term value creation

 Pharmaceutical

Expect to deliver above-market growth in the near- and long-term through portfolio maximization and R&D investment

 MedTech

Continue to focus on improved execution through market share momentum and enhanced cadence of innovation

 Consumer Health

Deliver science-backed innovation and digital, consumer-centric solutions while advancing towards the creation of a successful new standalone industry leader

## Key Industry Recognitions & Accolades

**FORTUNE** #15 World's Most Admired Companies List, #1 in Pharmaceutical Category in 2021

**WSJ** #7 The Best-Managed Companies of 2021


**Forbes** 3<sup>rd</sup> Consecutive Year in the Top 50 Best Employers for Diversity in 2021


**Gartner** #3 Supply Chain Top 25 for 2021


**FAST COMPANY** Top 10: J&J MedTech Earned a Spot in the 2022 Most Innovative Health Companies List

## Environmental, Social & Governance

**21** Ambitious Health for Humanity 2025 goals addressing pandemics and epidemics, global health equity, our people, planet and partners

 Approximately 70% of our Janssen COVID-19 vaccine supply was made available to low- and middle-income countries in 2021


 Recognized in 2021 with a CDP Climate Change A List rating for the fourth consecutive year

 Inclusion in FTSE4Good Index Series, which measures the performance of companies demonstrating good ESG practices

## Value Creation Through:

### R&D Investment and Product Innovation

 **#2** Ranked Pharm company in 2021 R&D investment<sup>1</sup>

 **50** Anticipated transformational therapies filed through 2025<sup>2</sup>

 **>20** Significant products launched in MedTech throughout 2021

### Strategic Partnerships, Acquisitions & Licensing<sup>3</sup>

**147** Innovation Deals

**20** New Equity Investments

**3** Acquisitions and Noteworthy Licensing Agreements

<sup>1</sup> Per Capital IQ <sup>2</sup> Transformational therapies includes both novel therapies and product expansions  
<sup>3</sup> Strategic partnerships, acquisitions & licensing related to 2021 activity



# Delivering Long-Term Value for our Stakeholders

## Our Capital Allocation Priorities



**Fuel** internal growth opportunities through R&D investment



**Deliver** competitive dividend




**Pursue** value creating mergers, acquisitions, partnerships & licensing agreements



**Evaluate** share repurchase programs with excess capital

### Free Cash Flow<sup>1</sup>

Dollars in Billions



## A Strong, Consistent, Sustainable Business

~6% Operational sales growth<sup>2</sup>

~8% Adjusted EPS growth<sup>3</sup>

Compound annual growth over the last 20 years



~25%

of sales come from products launched in the past 5 years



>70%

of sales come from #1 or #2 global market share position



13.2%

10-Year total return to shareholders



60

Consecutive years of dividend increases<sup>4</sup>


AAA

Rated Balance Sheet

## Sales by Business Segment

Dollars in Billions

Percent Change vs. 2020



	Reported	Operational <sup>2</sup>	Adjusted Operational <sup>5</sup>
Consumer Health	4.1%	2.8%	3.8%
Pharmaceutical	14.3	13.1	13.6
MedTech*	17.9	16.2	16.8
Worldwide	13.6%	12.2%	12.8%

\*2021 MedTech growth positively impacted by COVID-19 impacts in prior year

## 29 Platforms / Products >\$1 Billion in Annual Sales<sup>6</sup>

\* Includes Rounding

Consumer Health (4)

Pharmaceutical (14)

MedTech (11)

Neutrogena

LISTERINE

Johnson's

TYLENOL

Stelara<sup>®</sup>  
(Secukinumab)

DARZALEX<sup>®</sup>  
(daratumumab)

imbruvica<sup>®</sup>  
(ibrutinib)

INVEGA SUSTENNA<sup>®</sup>  
(paliperidone palmitate)

Remicade<sup>®</sup>  
(infliximab)

Xarelto<sup>®</sup>  
(rivaroxaban)

Zytiga<sup>®</sup>  
(abiraterone acetate)

Simponi<sup>®</sup>  
(golimumab)

Tremfya<sup>®</sup>  
(guselkumab)

Symtuza<sup>®</sup>  
(osimertinib)

Erleada<sup>®</sup>  
(apalutamide)

Upravi<sup>®</sup>  
(saxipipazone)

Opsumit<sup>®</sup>  
(macitentan)

PREZISTA<sup>®</sup>  
(darunavir)

Knees

Hips

Spine

Trauma

Endcutters

Biosurgery

Energy

Wound Closure


Electrophysiology

Contact Lens

Surgical Vision


## Sales by Geographic Area

Dollars in Billions




## Net Earnings

Dollars in Billions



## Earnings Per Share

Dollars



Note: All data included is based on 2021 full year, unless noted otherwise. Reference Non-GAAP reconciliation schedules in the Investors section at Investor.jnj.com. <sup>1</sup> Non-GAAP measure; defined as operating cash flow less capital spending. <sup>2</sup> Non-GAAP measure; excludes the impact of translational currency. <sup>3</sup> Non-GAAP measure; excludes intangible amortization expense, and special items. <sup>4</sup> Includes dividend declared in April 2022. <sup>5</sup> Non-GAAP measure; excludes the net impact of acquisitions and divestitures and translational currency <sup>6</sup> SIMPONI includes SIMPONI and SIMPONI ARIA; PREZISTA includes PREZISTA AND PREZCOBIX

\*2017 includes impact of U.S. Tax Cuts and Jobs Act  
\*\*2020 Earnings decline driven by COVID-19 impact